A European consortium of 19 partners has been awarded EUR 6.5 million by the European Union, marking the largest EU grant to psychedelic research to date and the first time that the EU has funded a multi-site clinical study into psychedelic-assisted therapy.
Norrsken Mind adopts a shared leadership model and appoints Marcus Stråth as Co-Managing Director alongside Emma Christersson, current Managing Director. Marcus joins Norrsken Mind from the strategic communications advisory firm Brunswick Group. He has previously supported Norrsken Mind as Head of Communication.
Norrsken Mind raises 36 MSEK to support research on psychedelic substances and awards grants to research at Karolinska Institutet and Umeå University
We actively raise funds for research. We have currently raised SEK 36 million and seek to raise more over the coming years. Read more about how you can contribute and support our work here.
We provide grant opportunities to advance the field of psychedelic science in Europe. Previous research funded by Norrsken Mind has focused on improving the scientific understanding of psychedelics and facilitating the development of new mental health treatments.
We support educational efforts to inform the public and mental health stakeholders about the current research on psychedelic-assisted treatments.
By fostering partnerships and actively working to promote collaboration across Europe, we can accelerate scientific progress.
Norrsken Mind has funded multiple research studies and projects, and we intend to fund many more. We are also funding efforts aimed at education and supporting the implementation of safe, effective and patient-centered treatments. Do you need funding for a project related to psychedelic science?
The twenty-first century has seen a revival of psychedelic research, largely funded by philanthropy and driven by researchers at universities such as Johns Hopkins University and Imperial College London. This research has demonstrated the potential of psychedelic-assisted therapies in treating mental health conditions. However, more research is needed to understand if, how, and for whom these treatments may work.
“Research on psychedelic-assisted treatments is one of the most promising lines of research in the field of psychiatry right now. With the right funding and conditions in place, we can accelerate psychedelic science and help researchers investigate more effective treatment options for patients in need.”
Managing Director, Norrsken Mind